IL6 and rheumatoid arthritis: One of the biologic DMARDs that demonstrated its effectiveness in the management of active and progressive RA is tocilizumab (TOZ), which is an interleukin-6 (IL-6) inhibitor with a low immunogenicity risk, flexible route of administration (intravenous (IV) and subcutaneous (SC)), and can be self-administered subcutaneously once-weekly [13].